Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy

Laryngoscope

Volumn 122, Issue 3, 2012, Pages 495-497

  Karnezis, Tom T ^a   Davidson, Terence M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Avastin; bevacizumab; epistaxis; Hereditary hemorrhagic telangiectasia; Level of Evidence: 4; vascular endothelial growth factors

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; EPISTAXIS; FEMALE; FOLLOW UP; HUMAN; MALE; NEBULIZER; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, INTRANASAL; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NASAL MUCOSA; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857451995     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.22501     Document Type: Article

References (15)

1. Brunet G, Lesca G, Genin E,. Thirty years of research into Rendu-Osler-Weber disease in France: historical demography, population genetics, and molecular biology. Popul Engl Ed 2009; 64: 273-291.
2. Dakeishi M, Shioya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Human Mutat 2002; 19: 140-148. (Pubitemid 34121805)
3. Kjeldsen AD, Vase P, Green A,. Hereditary hemorrhagic telangiectasia [HHT]: a population-based study of prevalence and mortality in Danish HHT patients. J Intern Med 1999; 245: 31-39. (Pubitemid 29049140)
4. Plauchu H, de Chadarevian JP, Bideau A, Robert JM,. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291-297. (Pubitemid 19146524)
5. Shovlin CL, Guttmacher AE, Buscarinni E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-67. (Pubitemid 30127562)
6. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor β1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818-828.
7. Braverman IM, Keh A, Jacobsen BS,. Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J Invest Dermatol 1990; 95: 422-427. (Pubitemid 20331987)
8. Simonds J, Miller F, Mandel J, Davidson TM,. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119: 988-992.
9. Chen S, Karnezis TT, Davidson TM,. Safety of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia associated epistaxis. Laryngoscope 2011; 121: 644-646.
10. Davidson TM, Olitsky SE, Wei JL,. Hereditary hemorrhagic telangiectasia/Avastin. Laryngoscope 2010; 120: 432-435.
11. Karnezis TT, Davidson TM,. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia associated epistaxis. Laryngoscope 2011; 121: 636-638.
12. Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA,. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010; 120: 838-843.
13. Richmon JD, Tian Y, Husseman J, Davidson TM,. Use of a sprayed fibrin hemostatic sealant after laser therapy for hereditary hemorrhagic telangiectasia epistaxis. Am J Rhinol 2007; 21: 187-191. (Pubitemid 46846349)
14. Schaal S, Kaplan HJ, Tezel TH,. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008; 115; 2199-2205.
15. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT,. Tachyphylaxis after intravitreal Bevacizumab for exudative age-related macular degeneration. Retina 2009; 29: 723-731.